OMERS ADMINISTRATION Corp Buys Shares of 7,400 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

OMERS ADMINISTRATION Corp bought a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 7,400 shares of the company's stock, valued at approximately $410,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Jennison Associates LLC increased its holdings in Tarsus Pharmaceuticals by 14.8% in the fourth quarter. Jennison Associates LLC now owns 2,500,132 shares of the company's stock worth $138,432,000 after buying an additional 321,552 shares during the last quarter. Barclays PLC grew its position in Tarsus Pharmaceuticals by 345.9% in the third quarter. Barclays PLC now owns 98,663 shares of the company's stock worth $3,246,000 after acquiring an additional 76,538 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth $1,107,000. Bleakley Financial Group LLC bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at $323,000. Finally, Northern Trust Corp raised its holdings in shares of Tarsus Pharmaceuticals by 12.6% during the 4th quarter. Northern Trust Corp now owns 357,616 shares of the company's stock valued at $19,801,000 after purchasing an additional 40,061 shares in the last quarter. 90.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on TARS shares. Oppenheimer increased their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. Jefferies Financial Group increased their price objective on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Barclays cut their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. HC Wainwright reaffirmed a "buy" rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Finally, The Goldman Sachs Group lifted their price target on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research report on Monday, May 5th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $66.33.

Insider Buying and Selling

In related news, CEO Bobak R. Azamian sold 6,000 shares of the firm's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $50.00, for a total value of $300,000.00. Following the completion of the transaction, the chief executive officer now directly owns 824,106 shares of the company's stock, valued at $41,205,300. This trade represents a 0.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Bryan Wahl sold 3,341 shares of Tarsus Pharmaceuticals stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $154,654.89. Following the sale, the general counsel now owns 58,057 shares in the company, valued at $2,687,458.53. This represents a 5.44% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,542 shares of company stock valued at $1,581,173. 8.25% of the stock is owned by company insiders.

Tarsus Pharmaceuticals Price Performance

NASDAQ TARS opened at $45.01 on Tuesday. The stock has a 50-day simple moving average of $48.01 and a 200 day simple moving average of $49.22. Tarsus Pharmaceuticals, Inc. has a twelve month low of $20.08 and a twelve month high of $57.28. The stock has a market capitalization of $1.89 billion, a PE ratio of -11.81 and a beta of 0.94. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $78.34 million for the quarter, compared to the consensus estimate of $72.50 million. Research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Want to see what other hedge funds are holding TARS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.